Literature DB >> 21139151

Unacceptable side-effects associated with a hyperosmolar vaginal microbicide in a phase 1 trial.

C J Lacey1, S Woodhall, Z Qi, S Sawant, M Cowen, S McCormack, S Jiang.   

Abstract

We carried out a phase 1 trial of a candidate vaginal microbicide gel against HIV-1 and other sexually transmitted diseases, which contained cellulose acetate 1,2-benzenedicarboxylate (also known as cellulose acetate phthalate) in a glycerol-based vehicle. We had to terminate the study after five women had completed dosing, due to all women experiencing unacceptable vulvo-vaginal side-effects. Further investigations showed that the gel had a very high osmolality, which we believe led to excessive fluid transudation across the vaginal mucosa and acute mucosal dysfunction. We also showed that the rheology of the gel changed dramatically on fluid dilution. The osmolality and rheology of candidate microbicides and other genital mucosal products should therefore be analysed and considered at an early stage of product development.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21139151     DOI: 10.1258/ijsa.2010.010215

Source DB:  PubMed          Journal:  Int J STD AIDS        ISSN: 0956-4624            Impact factor:   1.359


  16 in total

Review 1.  A review of nanotechnological approaches for the prophylaxis of HIV/AIDS.

Authors:  Abhijit A Date; Christopher J Destache
Journal:  Biomaterials       Date:  2013-05-28       Impact factor: 12.479

2.  Size-dependent biodistribution of thiol-organosilica nanoparticles and F4/80 protein expression in the genital tract of female mice after intravaginal administration.

Authors:  Aziz Awaad; Michihiro Nakamura
Journal:  Histochem Cell Biol       Date:  2021-03-03       Impact factor: 4.304

3.  Pharmaceutically Acceptable Carboxylic Acid-Terminated Polymers Show Activity and Selectivity against HSV-1 and HSV-2 and Synergy with Antiviral Drugs.

Authors:  Tejabhiram Yadavalli; Sudipta Mallick; Pratikkumar Patel; Raghuram Koganti; Deepak Shukla; Abhijit A Date
Journal:  ACS Infect Dis       Date:  2020-10-20       Impact factor: 5.084

4.  Formulation development and evaluation of innovative two-polymer (SR-2P) bioadhesive vaginal gel.

Authors:  Satheesh Podaralla; Carsten Alt; Gita N Shankar
Journal:  AAPS PharmSciTech       Date:  2014-04-30       Impact factor: 3.246

Review 5.  The importance of the vaginal delivery route for antiretrovirals in HIV prevention.

Authors:  Lindsay M Ferguson; Lisa Cencia Rohan
Journal:  Ther Deliv       Date:  2011-12

6.  Sustained release silk fibroin discs: Antibody and protein delivery for HIV prevention.

Authors:  Burcin Yavuz; Jessica L Morgan; Carolina Herrera; Kristin Harrington; Bernardo Perez-Ramirez; Patricia J LiWang; David L Kaplan
Journal:  J Control Release       Date:  2019-03-12       Impact factor: 9.776

7.  Formulating a sulfonated antiviral dendrimer in a vaginal microbicidal gel having dual mechanisms of action.

Authors:  Russell J Mumper; Michael A Bell; David R Worthen; Richard A Cone; Gareth R Lewis; Jeremy R A Paull; Thomas R Moench
Journal:  Drug Dev Ind Pharm       Date:  2009-05       Impact factor: 3.225

8.  Thermosensitive Gel Containing Cellulose Acetate Phthalate-Efavirenz Combination Nanoparticles for Prevention of HIV-1 Infection.

Authors:  Abhijit A Date; Annemaria Shibata; Emily McMullen; Krista La Bruzzo; Patrick Bruck; Michael Belshan; You Zhou; Christopher J Destache
Journal:  J Biomed Nanotechnol       Date:  2015-03       Impact factor: 4.099

9.  Preformulation and Vaginal Film Formulation Development of Microbicide Drug Candidate CSIC for HIV prevention.

Authors:  Tiantian Gong; Wei Zhang; Michael A Parniak; Phillip W Graebing; Bernard Moncla; Phalguni Gupta; Kerry M Empey; Lisa C Rohan
Journal:  J Pharm Innov       Date:  2017-03-03       Impact factor: 2.750

10.  Polyanionic candidate microbicides accelerate the formation of semen-derived amyloid fibrils to enhance HIV-1 infection.

Authors:  Suiyi Tan; Lu Lu; Lin Li; Jixiang Liu; Yelena Oksov; Hong Lu; Shibo Jiang; Shuwen Liu
Journal:  PLoS One       Date:  2013-03-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.